Annovis Bio, Inc. (ANVS)
0.9934
-0.06
(-5.39%)
USD |
NYSE |
Oct 16, 16:00
1.00
+0.01
(+0.66%)
Pre-Market: 20:00
Annovis Bio Net Income (Quarterly) : -14.82M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.82M |
| March 31, 2026 | -17.61M |
| December 31, 2025 | -9.834M |
| September 30, 2025 | -7.263M |
| June 30, 2025 | -6.220M |
| March 31, 2025 | -5.537M |
| December 31, 2024 | -5.865M |
| September 30, 2024 | -12.64M |
| June 30, 2024 | -5.020M |
| March 31, 2024 | -1.067M |
| December 31, 2023 | -22.21M |
| September 30, 2023 | -14.72M |
| June 30, 2023 | -9.537M |
| March 31, 2023 | -9.737M |
| December 31, 2022 | -3.095M |
| September 30, 2022 | -6.432M |
| June 30, 2022 | -5.936M |
| Date | Value |
|---|---|
| March 31, 2022 | -5.234M |
| December 31, 2021 | -5.915M |
| September 30, 2021 | -2.848M |
| June 30, 2021 | -2.525M |
| March 31, 2021 | -3.200M |
| December 31, 2020 | -1.705M |
| September 30, 2020 | -1.006M |
| June 30, 2020 | -2.310M |
| March 31, 2020 | -0.4416M |
| December 31, 2019 | -0.2013M |
| September 30, 2019 | -0.2541M |
| June 30, 2019 | -0.3447M |
| March 31, 2019 | -0.1909M |
| December 31, 2018 | -0.1681M |
| September 30, 2018 | -0.1377M |
| June 30, 2018 | -0.2181M |
| March 31, 2018 | -0.1899M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 14.82M |
| EPS Diluted (Quarterly) | -0.395 |
| Enterprise Value | 23.60M |
| Earnings Yield | -180.4% |
| Normalized Earnings Yield | -182.20 |